Running Point Capital Advisors’s Epizyme, Inc EPZM Stock Holding History

Running Point Capital Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,000	Closed	-$29K	–	241
2022 Q2	$29K	Hold	20,000	–	–	0.02%	174
2022 Q1	$23K	Buy	+20,000	New	+$32.6K	0.01%	181

Other funds holding EPZM

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Running Point Capital Advisors's EPZM Position: Q3 2022 in Review

Running Point Capital Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 20,000 shares — an estimated $29K sold.

Running Point Capital Advisors first reported a position in EPZM in Q1 2022 and held it in 2 quarters. The position peaked at $29K in Q2 2022. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

Running Point Capital Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
Running Point Capital Advisors sold 20,000 Epizyme, Inc shares in Q3 2022, an estimated $29K.
Running Point Capital Advisors first reported a position in Epizyme, Inc in Q1 2022 and held it in 2 quarters.
Running Point Capital Advisors's Epizyme, Inc position peaked at $29K in Q2 2022.
0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Running Point Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.